{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:21:51Z","timestamp":1771438911840,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"DOI":"10.7759\/cureus.103847","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:59:01Z","timestamp":1771437541000},"source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy and the Skin: Understanding Dermatologic Side Effects"],"prefix":"10.7759","author":[{"given":"Pooja","family":"Unnikrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirankanth","family":"Vudayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Diddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha Sri","family":"Akkineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vunnava","family":"Sri Koulini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakka","family":"Gayathri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture ME","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006, 6:803-12. 10.1038\/nrc1970","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud V","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, et al.. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016, 26:427-43. 10.1684\/ejd.2016.2833","journal-title":"Eur J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous toxicities of cancer therapy","volume":"14","author":"Alley E","year":"2002","unstructured":"Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002, 14:212-6. 10.1097\/00001622-200203000-00012","journal-title":"Curr Opin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1102","article-title":"Serpentine supravenous hyperpigmentation","volume":"5","author":"Jamalpur I","year":"2017","unstructured":"Jamalpur I, Mogili HR, Koratala A. Serpentine supravenous hyperpigmentation. Clin Case Rep. 2017, 5:1546-7. 10.1002\/ccr3.1102","journal-title":"Clin Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller KK","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014, 71:787-94. 10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02039-3","article-title":"Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil","volume":"128","author":"Yang B","year":"2023","unstructured":"Yang B, Xie X, Lv D, et al.. Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. Br J Cancer. 2023, 128:219-31. 10.1038\/s41416-022-02039-3","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine","volume":"12","author":"Gressett SM","year":"2006","unstructured":"Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006, 12:131-41. 10.1177\/1078155206069242","journal-title":"J Oncol Pharm Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini AM","year":"2003","unstructured":"Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003, 14:333-7. 10.1093\/annonc\/mdg050","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_216_20","article-title":"Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group","volume":"87","author":"Kumar S","year":"2021","unstructured":"Kumar S, Bhattacharjee R, Kambhampati SB, Narang T, Kanwar AJ, Vinay K. Chemotherapy-induced reticulate pigmentation in three Indian patients including a case in the pediatric age group. Indian J Dermatol Venereol Leprol. 2021, 87:386-8. 10.25259\/IJDVL_216_20","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li T","year":"2009","unstructured":"Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009, 4:107-19. 10.1007\/s11523-009-0114-0","journal-title":"Target Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.2004116","article-title":"Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors","volume":"17","author":"Du J","year":"2021","unstructured":"Du J, Yan H, Xu Z, Yang B, He Q, Wang X, Luo P. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert Opin Drug Metab Toxicol. 2021, 17:1311-25. 10.1080\/17425255.2021.2004116","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(\u2606)","volume":"32","author":"Lacouture ME","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, et al.. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(\u2606). Ann Oncol. 2021, 32:157-70. 10.1016\/j.annonc.2020.11.005","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04466.x","article-title":"The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients","volume":"27","author":"Ra HS","year":"2013","unstructured":"Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol. 2013, 27:e53-9. 10.1111\/j.1468-3083.2012.04466.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio A","year":"2009","unstructured":"Osio A, Mateus C, Soria JC, et al.. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009, 161:515-21. 10.1111\/j.1365-2133.2009.09214.x","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.12.004","article-title":"Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review","volume":"17","author":"Lacouture ME","year":"2018","unstructured":"Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018, 17:85-96. 10.1016\/j.clcc.2017.12.004","journal-title":"Clin Colorectal Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.06.007","article-title":"Adverse cutaneous reactions to chemotherapeutic drugs","volume":"38","author":"Haynes D","year":"2020","unstructured":"Haynes D, Ortega-Loayza AG. Adverse cutaneous reactions to chemotherapeutic drugs. Clin Dermatol. 2020, 38:712-28. 10.1016\/j.clindermatol.2020.06.007","journal-title":"Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16361","article-title":"Evaluation of chemotherapy-induced cutaneous side effects in cancer patients","volume":"61","author":"Saadet ED","year":"2022","unstructured":"Saadet ED, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. Int J Dermatol. 2022, 61:1519-26. 10.1111\/ijd.16361","journal-title":"Int J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_168_22","article-title":"An observational study of cutaneous manifestations in patients on chemotherapy and radiation therapy for internal malignancies at a tertiary care center","volume":"13","author":"Tandel JJ","year":"2022","unstructured":"Tandel JJ, Polra RV, Parmar D, Srivastava P, Panchal R, Nair PA. An observational study of cutaneous manifestations in patients on chemotherapy and radiation therapy for internal malignancies at a tertiary care center. Indian Dermatol Online J. 2022, 13:757-64. 10.4103\/idoj.idoj_168_22","journal-title":"Indian Dermatol Online J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_65_17","article-title":"Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study","volume":"63","author":"Biswal SG","year":"2018","unstructured":"Biswal SG, Mehta RD.  Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study. Indian J Dermatol. 2018, 63:41-6. 10.4103\/ijd.IJD_65_17","journal-title":"Indian J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan B","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015, 26:2017-26. 10.1093\/annonc\/mdv244","journal-title":"Ann Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12205","article-title":"Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions","volume":"53","author":"Curry JL","year":"2014","unstructured":"Curry JL, Torres-Cabala CA, Kim KB, et al.. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014, 53:376-84. 10.1111\/ijd.12205","journal-title":"Int J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14145","article-title":"Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy","volume":"49","author":"Seervai RN","year":"2022","unstructured":"Seervai RN, Cho WC, Chu EY, et al.. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol. 2022, 49:61-81. 10.1111\/cup.14145","journal-title":"J Cutan Pathol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.156191","article-title":"Serpentine supravenous hyperpigmentation induced by docetaxel","volume":"81","author":"Das A","year":"2015","unstructured":"Das A, Kumar D, Mohanty S, Mondal AK, Chowdhury SN, Bandyopadhyay D. Serpentine supravenous hyperpigmentation induced by docetaxel. Indian J Dermatol Venereol Leprol. 2015, 81:434. 10.4103\/0378-6323.156191","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.05.013","article-title":"Cutaneous adverse reactions of anticancer agents","volume":"37","author":"Kaul S","year":"2019","unstructured":"Kaul S, Kaffenberger BH, Choi JN, Kwatra SG. Cutaneous adverse reactions of anticancer agents. Dermatol Clin. 2019, 37:555-68. 10.1016\/j.det.2019.05.013","journal-title":"Dermatol Clin"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","volume":"40","author":"Deutsch A","year":"2020","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2020, 40:485-500. 10.1200\/EDBK_289911","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450095-chemotherapy-and-the-skin-understanding-dermatologic-side-effects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:59:01Z","timestamp":1771437541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450095-chemotherapy-and-the-skin-understanding-dermatologic-side-effects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.103847","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}